Lentivectors are potential vaccine delivery vehicles because they can efficiently transduce a variety of non-dividing cells, including antigen-presenting cells, and do not cause expression of extra viral proteins. To improve safety while retaining efficiency, a dendritic cell (DC)-specific lentivector was constructed by pseudotyping the vector with an engineered viral glycoprotein derived from Sindbis virus. We assessed the level of anti-tumor immunity conferred by this engineered lentivector encoding the melanoma antigen gp100 in a mouse model. Footpad injection of the engineered lentivectors results in the best antigen-specific immune response as compared with subcutaneous and intraperitoneal injections. A single prime vaccination of the engineered lentivectors can elicit a high frequency (up to 10%) of gp100-specific CD8 þ T cells in peripheral blood 3 weeks after the vaccination and this response will be maintained at around 5% for up to 8 weeks. We found that these engineered lentivectors elicited relatively low levels of anti-vector neutralizing antibody responses. Importantly, direct injection of this engineered lentivector inhibited the growth of aggressive B16 murine melanoma. These data suggest that DC-specific lentivectors can be a novel and alternative vaccine carrier with the potential to deliver effective anti-tumor immunity for cancer immunotherapy.
Introduction
Induction of an antigen-specific immune response and maintaining a long-term immunologic effect to protect against subsequent diseases is the ultimate goal of current vaccine research. Studies of immune reactions and their specific responses towards tumor cells have revealed the central role of dendritic cells (DCs) in the initiation of anti-tumor immune responses. 1, 2 In light of the described functional features of DCs and their remarkable ability to present antigens to T cells, 3, 4 significant efforts have been devoted to developing DC-based immunization strategies for delivering tumor-associated antigen to the immune system. 5, 6 In these protocols, the DCs must be in some way engineered to present tumor-specific antigens, either by loading the DCs with exogenous proteins/peptides or by transfecting DCs with tumor-associated antigenencoding DNAs/RNAs. Although substantial progress has been made on many aspects of DC-based vaccine methods, many challenges still remain. 5, [7] [8] [9] In vivo targeting of vaccines to DCs is highly desirable and there is growing interest in developing delivery systems with cell-specific capabilities to improve the safety and efficiency of DC-based vaccination. 10, 11 Among the many delivery strategies, recombinant viral vectors have been proven to be effective for the delivery of antigen-encoded genes to DCs for direct immunization. 12, 13 Adenovirus vectors were shown to be capable of transducing and expressing transgenes in both human or mouse DCs. 14, 15 However, their applications are limited due to the high prevalence of pre-existing immunity to adenoviral proteins. 16, 17 Retroviral vectors based on murine leukemia virus have also been used for antigen delivery, 18 however, these murine leukemia virusbased vectors only infect dividing cells. Injection of murine leukemia virus-based vectors into mice resulted in a low level stimulation of immunity. 19 Several studies have shown that HIV-1-based lentivectors are able to deliver genes into non-dividing and less proliferating cells, including peripheral DCs. [20] [21] [22] [23] One advantage of using the lentivector system is that the vector does not encode any major viral proteins. This eliminates the generation of competition of anti-vector responses, which competes with the generation of anti-transgene responses. Therefore, lentivectors have thus been proposed to be an ideal vector tool for vaccine delivery. 20, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Based on the study of Sindbis virus, a member of the Alphavirus genus and the Togaviride family, we have reported a mutant Sindbis virus glycoprotein, (SVGmu) which can specifically bind to DC-specific intracellular adhesion molecule (ICAM) 3 grabbing non-integrin (DC-SIGN, CD209). 34 DC-SIGN is a C-type lectin-like receptor and is expressed on DCs and macrophages. 35 Taking advantage of the interaction between DC-SIGN and the Sindbis virus glycoprotein, 36, 37 we have engineered lentivectors pseudotyped with this mutant Sindbis virus glycoprotein and achieved DC-specific gene delivery in vivo. 34 Our previous studies have shown that direct administration of targeting lentivectors expressing chicken ovalbumin (OVA) antigen could induce strong antigenspecific T cell and antibody responses. 34 In this study, we aim to develop HIV-1-based lentivectors capable of generating efficient and specific expression of a tumor antigen in mouse DCs in vivo, and evaluate the potential of this lentivector-based vaccine strategy to prevent tumor growth in mice. Previous experiments showed that an autologous antigen failed to generate measurable immune reactivity in a mouse model of melanoma, but a xenogenetic antigen from human could induce certain immune responses and it has the cross-reactivity to the mouse counterpart. 38 Human melanoma-associated antigen gp100 (hgp100) is a well-known melanoma differentiation antigen and is about 75% identical to the mouse melanoma gp100 gene. 39 Several studies have shown that some level of protective antimelanoma immunity could be induced in mice after hgp100-specific immunization by mRNA, DNA, peptide-pulsed DCs and adenovirus-mediated gene transfer. [40] [41] [42] These studies suggested that the full length of gp100, containing the N-terminal signal sequence and the last 70 residues in the C-terminus, can be presented by both MHC class I and MHC class II molecules when expressed endogenously. 43 In the current study, we constructed a DC-specific lentivector (designated as FUW-hgp100/SVGmu) encoding the fulllength hgp100 antigen. Our data showed that a strong antigen-specific immune response could be induced by direct injection of the DC-specific lentivector in vivo and that the anti-tumor response could significantly slow tumor growth upon challenge with murine melanoma tumor cells.
Materials and methods

Mice
Female 6-10 weeks-old C57BL/6 (termed as B6) mice were purchased from Charles River Breeding Laboratories (Wilmington, MA). The Pmel17 T cell receptor (TCR) transgenic mice were obtained from The Jackson Laboratories (Bar Harbor, ME). All mice were held under specific pathogen-reduced conditions in the Animal Facility of the University of Southern California (USA). All experiments were performed in accordance with the guidelines set by the National Institute of Health and the University of Southern California on the Care and Use of Animals.
Plasmid construction
The SVGmu plasmid was constructed previously in our laboratory. 34 Briefly, the glycoprotein from a laboratory strain of Sindbis virus (NCBI accession number: J02363) was PCR amplified and cloned into pcDNA3 (Invitrogen, Carlsbad, CA). In order to disrupt the inherent binding to heparin sulfate glycosaminoglycan structures, we deleted amino acids 61-64 of the E3 protein and performed the mutation of amino acids 157KE158 into 157AA158 in the E2 protein. A hemagglutinin epitope tag sequence (MYPYDVPDYA) was also inserted between amino acids 71 and 74 of the E2 protein to facilitate the analysis of SVGmu expression.
To construct the FUW-hgp100 plasmid (Figure 1a ), the hgp100 gene was PCR amplified (forward primer, 5
0 -AC TCGAATTCATGGATCTGGTGCTAAAAAGATGCC TTCTTCATTTG-3 0 ; backward primer, 5 0 -ACTCCTCG AGTCAGACCTGCTGCCCACTGAGGAGGGG-3 0 ), and the resulting complementary DNA was cloned into the pENTR vector (Invitrogen) to yield pENTR-hgp100. FUW-Gateway plasmid was constructed in our lab by inserting the Gateway gene into FUW under the control of the human ubiquitin-C promoter. The Gateway recombination cloning technique (Invitrogen) was then applied to construct FUW-hgp100. The HIV-1-based lentiviral transfer plasmid FUGW was described previously. 44 Lentivector production and concentration Lentivectors were prepared by a standard calcium phosphate precipitation protocol. The 293T cells cultured in a 6-cm culture dish (BD Falcon, Bedford, MA) were transiently transfected with the lentiviral backbone plasmid FUGW or FUW-hgp100 (5 mg), along with 2.5 mg of the envelope plasmid SVGmu and other packaging plasmids (pMDLg/pRRE and pRSV-Rev). 45 The viral supernatants were harvested between 48-72 h ; mBMDCs, 293T/hDC-SIGN, or 293T/mDC-SIGN) were seeded in a 24-well culture dish (BD Falcon) and spin-infection was conducted at 2500 r.p.m. and 30 1C for 90 min using a RT Legend centrifuge (Thermo Scientific, Ashville, NC) with 1 ml of fresh lentiviral supernatant per well. Following the spininfection, the supernatants were replaced with fresh culture medium and incubated for an additional 3-5 days at 37 1C with 5% CO 2 . The GFP expression was evaluated by flow cytometry analysis.
DC generation
We generated mouse bone marrow-derived DCs (mBMDCs) by a 6-day culture protocol with cytokines granulocyte-monocyte colony stimulating factor and interleukin-4 as previously described. 46 Briefly, mouse bone marrow cells were flushed from the femurs and tibias of B6 mice and the red blood cells were depleted by lysis with TAC buffer. Cells were then cultured in fresh RPMI medium containing 10% fetal bovine serum (C10) and granulocyte-monocyte colony stimulating factor (1:20 J558L conditioned medium) for 3 days at 37 1C with 5% CO 2 . On day 3 of culture, additional C10 medium containing granulocyte-monocyte colony stimulating factor was added into the mBMDCs culture and the cells were incubated for another 3 days. On day 6, non-adherent and loosely adherent cells were harvested.
Flow cytometry and intracellular cytokine release assay Spleen cells were harvested from vaccinated mice 2 weeks postvaccination or peripheral blood was collected by retro-orbital draw at various time points. Then, red blood cells were removed by lysis using TAC buffer. To measure the hgp100-specific CD8 þ T-cell response, single-cell suspensions of collected cells were stained with the H-2D b /gp100 tetramer (KVPRNQDWL), along with anti-mouse CD8 and anti-mouse CD44 antibodies. Intracellular cytokine expression was detected using the Cytofix/Cytoperm plus kit (BD Biosciences, San Jose, CA) with GolgiPlug (BD Biosciences). Briefly, spleen cells (1 Â 10 6 cells per well) were cultured in a round-bottom 96-well plate in a total of 200 ml C10 medium with 5 mg ml À1 hgp100 peptide plus 0.67 ml ml À1 GolgiPlug for 6 h at 37 1C. Cells were washed and stained with antimouse CD4 and anti-mouse CD8 antibodies followed by intracellular anti-mouse interferon (IFN)-g staining.
Peptide-specific CD8
þ T-cell enzyme-linked immunosorbent spot assay The ex vivo recall response to the melanocyte peptide epitope was measured in spleen cells of immunized mice by stimulating cultures with the hgp100 peptide (KVPRNQDWL, GenScript). Briefly, a 96-well enzyme-linked immunosorbent spot plate (Millipore, Billerica, MA) was coated with an antimouse IFN-g antibody at 5 mg ml À1 (BD Biosciences) in coating buffer overnight at 4 1C. The plate was washed three times with phosphate-buffered saline and non-specific sites on the plate were blocked with 1% bovine serum albumin in phosphate-buffered saline for 1 h at room temperature. The spleen cells stimulated overnight by the hgp100 peptide were then added and the plate was incubated for 2 h at 37 1C and 5% CO 2 . The cells were discarded and the plate was washed three times with PBST. Biotinylated anti-IFN-g antibody (BD Biosciences) was added at 100 ml per well and the plate was incubated for another 2 h at room temperature. Avidinconjugated alkaline phosphatase (Chemicon) in 100 ml blocking buffer was then added and the samples were incubated for 1 h at room temperature. The plate was developed using NBT/BCIP phosphatase substrate solution (Millipore) and spots were counted using a Zeiss ELISPOT reader (Carl Zeiss MicroImaging GmbH, Gottingen, Germany).
T-cell proliferation assay
Spleen cells collected from the Pmel17 transgenic mice or lentivector-vaccinated mice were cultured with the lentivector-transduced or hgp100 peptide-pulsed mBMDCs at the indicated ratios. Three days later, T-cell proliferation was measured using the [ Lentivector-specific neutralizing antibody measurement Lentivector-specific neutralizing antibody responses were assessed by a GFP-based virus neutralization assay. The 293T/hDC-SIGN cells were plated at the density of 1 Â 10 4 cells per well in a 96-well plate. FUGW/SVGmu or FUGW/VsVg particles were then added at a multiplicity of infection of 2.5 (MOI ¼ 2.5) with twofold serial dilutions of serum from 10 3 ng p24 FUGW/SVGmu-or FUGW/VsVg-immunized mice in a total 200 ml volume. Spin infection was conducted at 2500 r.p.m. and 30 1C for 90 min using a RT Legend centrifuge and the supernatants were replaced with fresh culture media following the infection. After incubation for additional 3 days at 37 1C with 5% CO 2 , the GFP expression was evaluated by flow cytometry. The ninety percent neutralization titer was defined as the maximum serum dilution that neutralized 90% of GFP expression.
þ T cells were depleted using an anti-CD8 antibody (clone 2.43, Bio Express, West Lebanon, NH). Briefly, C57BL/6 mice were vaccinated with the lentivector FUWgp100/SVGmu via the footpad (f.p.) injection. Depletions were started 1 week before the tumor challenge. Mice were given intraperitoneal (i.p.) injections of 0.4 mg of the antibody every other day for 3 days. Flow cytometry analysis was employed to measure the level of CD8 depletion.
Immunization and tumor challenge
Wild-type B6 mice were administered targeting lentivectors by f.p., s.c. (in the flank of mice), or i.p. injection at the indicated dose. On day 14 postimmunization, blood was collected for the total serum immunoglobulin (Ig)G and IgM antibody enzyme-linked immunosorbent assay assays. Meanwhile, spleen cells were harvested for the hgp100-specific T-cell assay and the cytokine release assay. For the tumor challenge study, a dose of 2 Â 10 
Statistical analysis
The significance of the difference between groups in the experiments was evaluated by analysis of variance followed by a one-tailed Student's t-test.
Results
Targeting DC-SIGN-expressing cells in vitro DC-SIGN, a C-type lectin like receptor on certain subsets of DCs, can be used as a targeting receptor for antigen delivery to DCs. 10 Previous studies have already shown the promising applications of DC targeting through the surface DC-SIGN receptor. 47, 48 We have demonstrated that a lentivector enveloped with a mutant glycoprotein derived from Sindbis virus (designated as SVGmu, Figure 1 ), in which the mutation attenuates its binding capacity to cell surface heparin sulfate structures, displays transduction specificity to DCs. 34 We performed the study of targeted transduction to murine bone marrow-derived DCs (mBMDCs). The mBMDCs were generated from the murine bone marrow culture and the identity of the mBMDCs was confirmed by surface marker analysis after 6 days of culture (Figure 2a ). When these immature mBMDCs were exposed to the lentivector FUGW/SVGmu at various MOI, we found that the transduction efficiency increased when using a higher MOI, from 10% (MOI ¼ 1) to 34% (MOI ¼ 25) (Figure 2b ). Further analysis on these GFP þ cells showed that they were DC-SIGN þ CD11c þ DCs (data not shown), as was shown previously. 34 We then investigated whether the recombinant lentivector could be used to effectively deliver antigen to DCs to stimulate antigen-specific T-cell responses in vitro. The lentiviral transfer construct FUW-hgp100 was made by replacing the GFP gene in FUGW with the complementary DNA of the melanoma-specific antigen hgp100 (Figure 1a) . The mBMDCs were transduced with either FUW-hgp100/SVGmu (designated as DC/gp100) or FUGW/SVGmu, which encoded a GFP reporter (designated as DC/GFP). A 3 H-thymidine incorporation assay was conducted to evaluate the ability of vector-transduced DCs to process and present the hgp100 antigen to transgenic T cells harvested from Pmel17 transgenic mice. 49 After a 3-day co-culture of transduced DCs and T cells at the indicated ratios, the T cells stimulated by DC/ gp100 proliferated whereas the DC/GFP culture had only background proliferation (Figure 2c ). Our results demonstrated that the recombinant lentivector could specifically target DC-SIGN-expressing cells and effectively deliver the melanoma antigen to DCs, which are able to stimulate T cells in vitro.
Characterization of immune responses induced by targeting lentivectors
Previous animal studies on the adoptive transfer of ex vivo-generated DCs indicated that the delivery site of a DC preparation has a key role in the resulting immune responses. 50, 51 Thus, for our DC-directed immunization approach, it was necessary to perform a broad study comparing the response generated by different vaccination routes. Naive B6 mice were immunized with the targeting lentivector FUW-hgp100/SVGmu (transduction units (TU) ¼ 5 Â 10 6 ) by s.c., f.p. or i.p. injection. Fourteen days later, spleen cells were harvested from the immunized mice and tested for vaccine-specific CD8 To further analyze the differences among these three administration routes, we conducted experiments to measure the IFN-g secretion of the T cells from each immunization group in response to hgp100 peptide stimulation (Figure 3b) . Compared with the f.p. immunization resulting in more than 3% IFN-g þ CD8 þ cells, both s.c. and i.p. immunizations generated less than 1% IFN-g þ CD8 þ cells. We concluded that f.p. immunization with the lentivector FUW-hgp100/SVGmu induced stronger antigen-specific T-cell responses. A similar trend was also observed when we immunized mice with the DC-directed lentivector encoding a HIV-Gag gene. 52 We therefore utilized the f.p. route for vector administration in our subsequent studies.
We next performed a detailed analysis of the efficiency of the targeting lentivector vaccine for inducing antigenspecific CD8
þ T cell and antibody responses after f.p. administration of FUW-hgp100/SVGmu to naive B6 mice. A single dose of FUW-hgp100/SVGmu (5 Â 10 6 TU) was injected and spleen cells were harvested 14 days postimmunization for immune analysis. Spleen cells collected from the control mice or the lentivector-vaccinated Figure 3 Immune response analyses after a single dose lentivector vaccination. (a, b) B6 mice were immunized with 5 Â 10 6 TU of concentrated FUW-hgp100/SVGmu by three different injection routes as indicated and spleen cells were analyzed 2 weeks postimmunization. The presence of hgp100-specific CD8 þ T cells was measured by co-staining using gp100 tetramer and anti-mouse CD8 and anti-mouse CD44 antibodies. The percentage of CD44 þ tetramer þ cells from a representative mouse (upper) or from a group of mice was presented (a). Spleen cells were re-stimulated in the presence of hgp100 peptide and GolgiPlug (BD Biosciences) for 6 h. Then, cells were washed and stained with anti-mouse CD4 and anti-mouse CD8 antibodies followed by intracellular anti-mouse IFN-g staining. The percentage of IFN-g þ CD8 þ T cells from a representative mouse (upper) or from a group of mice (lower) was presented (b). The experiment was repeated three times. (c, d) Further analysis of the melanoma antigen-specific T-cell responses after a single dose f.p. injection. On day 14 postvaccination, mice were killed and T cells from both control and immunized mice were harvested. (c) The T-cell proliferation response was assessed by measuring the uptake of 3 H-thymidine after 3 days of culture with 5 mg ml À1 of the hgp100 peptide. (d) The indicated amount of T cells from control or immunized mice were cultured with or without the hgp100 peptide on an enzyme-linked immunosorbent spot plate overnight. Then, the plate was developed and spots were counted for each group. All experiments were triplicated and and error bars indicate mean±s.d.
Targeted lentivector vaccine against murine melanoma
HG Yang et al mice were cultured with the hgp100 peptide and 3 Hthymidine uptake was measured after 3 days of culture. As shown in Figure 3c , T cells from the vaccinated mice showed markedly higher proliferation upon the hgp100 peptide stimulation as compared with that of the control mice. A similar result was observed from an enzyme-linked immunosorbent spot assay on the same groups of T cells (Figure 3d ). All of these data further confirmed the antigen-specific immune response after a single injection of the DC-directed lentivector encoding hgp100.
To examine the serum antibody response, mouse sera were collected from animals on day 14 postimmunization and were assessed for the total hgp100-specific IgG and IgM levels. The titers for the hgp100 IgG and IgM were 1:60 000 and 1:6000, respectively (data not shown). This substantial anti-hgp100 antibody response was generated by a single-dose injection of the FUWhgp100/SVGmu lentivector without additional stimuli. These results demonstrated that an in vivo f.p. administration of the targeting lentivector FUW-hgp100/SVGmu can efficiently induce both cellular and humoral immune responses against the hgp100 antigen.
Anti-vector immunogenicity of DC-directed lentivectors
We performed a study to determine the anti-vector immunogenicity of the engineered lentivector vaccine in mice. Groups of C57/BL6 mice (n ¼ 4) were immunized with the indicated amount of vectors; the dose is based on the p24 viral protein measurement. Vaccine-elicited antibody immune responses were assessed by using a vectorspecific neutralizing antibody assay. As shown in Figure 4 , the naı¨ve mice immunized with FUGW/SVGmu developed certain vector-specific immune responses. At the dose of 10 2 ng p24 of FUGW/SVGmu (MOI ¼ 2.5), only a marginal vector-specific humoral immune response was elicited and the 90% neutralizing antibody titer was less than 10. At the dose of 10 3 ng p24, the non-targeting and widely used vesicular stomatitis virus glycoprotein (VsVg)-pseudotyped lentivector generated a much higher anti-vector immune response than that of SVGmubearing vector; the 90% neutralizing antibody titer was more than 10-fold higher for FUGW/VsVg. These data suggest that our DC-specific lentivector (FUGW/ SVGmu) has additional advantage of having lower antivector immunogenicity in mice.
Kinetic study of antigen-specific CD8
þ T-cell responses Tetramer staining was used to monitor the dynamic T-cell response against the melanoma antigen upon immunization. The peripheral blood was collected by retro-orbital bleeding at various time points after a single-dose vaccination of the targeting lentivector. The antigenspecific CD8 þ T cells were then enumerated by tetramer staining. The frequency of tetramer-positive T cells from a representative mouse is shown in Figure 5a and the average kinetic pattern of hgp100-specific CD8 þ T cells was shown in Figure 5b . Two weeks after immunization, more than 6% of the cells were tetramer þ CD8 þ T cells as compared with the percentage of tetramer þ CD8 þ T cells on week one (less than 2%). The highest level of tetramer þ CD8 þ T-cell responses was observed at week three postimmunization, when there were about 10% tetramer þ CD8 þ T cells in the peripheral blood. A significant reduction in the number of these T cells (7%) was detected at week four, after which the amount of hgp100-specific T cells was maintained at 5% until at least week eight.
Growth inhibition of B16 melanoma cells in vaccinated mice
A mouse tumor model was used to evaluate the level of tumor-protective immunity conferred by a single-dose administration of the DC-specific lentivector against a lethal challenge of wild-type B16 melanoma cells. B6 mice were immunized by a f.p. administration of FUWhgp100/SVGmu (5 Â 10 6 TU). The mice were challenged 2 weeks later by an s.c. injection of 2 Â 10 5 B16 melanoma cells (Figure 6a ). When the tumors reached certain size, the mice were killed and the spleen cells were harvested for an immune analysis. The mice vaccinated by FUWhgp100/SVGmu showed tumor-protective immunityone rejected tumor completely (data not shown) and the remaining animals had a significant suppression of tumor growth (Figure 6b ). Rapid tumor growth was seen for the control groups (no injection or injection with either phosphate-buffered saline or a lentivector lacking the melanoma antigen, FUW/SVGmu), confirming that the hgp100 immunogen was essential for the observed tumor growth-inhibiting immune response. Next, we harvested the splenocytes from animals challenged with the B16 melanoma cells for analysis of hgp100-specific T-cell immune responses and their correlations to tumor inhibition (Figure 6c ). Mice vaccinated with the FUW-hgp100/ To further confirm that the CD8 þ T cells are important for the observed tumor growth inhibition, we performed in vivo antibody depletion experiments using a monoclonal antibody specific for the mouse CD8 þ T cells. Two groups of mice were vaccinated with FUWhgp100/SVGmu and a non-immunization group was included as a control. The CD8 þ T cell depletion was initiated 1 week before the tumor challenge (Figure 7a ). Flow cytometric analysis showed that 490% of CD8 þ T cells were depleted by the antibody treatment and the mice was maintained at the CD8-depleted condition throughout the experiment (data not shown). As shown in Figure 7b , the control group showed a similarly rapid tumor growth. The vaccinated group without the CD8 depletion resulted in an obvious suppression of tumor growth due to the vaccine-induced tumor-protective immunity. In contrast, the CD8-depleted group had a less effect on the suppression of tumor growth, confirming the role of CD8 þ T cells for the antitumor immunity induced by FUW-hgp100/SVGmu.
Discussion
Lentivectors are potent vaccine carriers because they are able to mediate long-term transgene expression and maintain its presentation to antigen-presenting cells. 25 Additionally, the induced immune responses are supposed to be transgene-specific because the lentivectors are modified to lack the viral protein expression. 53 In this study, we described a targeting method to deliver tumorassociated antigen for DC-directed immunization in vivo. Our data demonstrates that the engineered lentivector has the ability to selectively transduce DCs and can be exploited in a tumor vaccine strategy to elicit functional cellular and humoral immune responses against tumors.
The surface of the designed lentivector used in this study was decorated by an engineered viral glycoprotein derived from the Sindbis virus. Earlier studies have shown that the Sindbis virus can infect cells through cell-surface heparin sulfate and/or the DC-SIGN protein. 36, 37, 54, 55 In light of fact that DC-SIGN is mainly expressed at high levels on the surface of immature DCs, 10 we hypothesized that the introduction of mutations to the Sindbis virus glycoprotein to disable its binding to heparin sulfate structures might afford an envelope protein that selectively recognizes DCs. 34 Consistent with our previous report, 34 we verified that a lentivector enveloped with the engineered Sindbis virus glycoprotein (SVGmu) could selectively transduce 293T cells expressing either human or murine DC-SIGN, as well as mBMDCs. Targeted transduction also allowed DCs to effectively express and present a melanoma antigen to stimulate the Â transgenic T cells in vitro.
We previously demonstrated that an OVA-encoding lentivector enveloped with SVGmu could efficiently elicit OVA-specific T cells upon s.c. immunization. 34 However, considering the broad tissue distribution of DCs, it was necessary to compare immune responses induced through other administration routes with the response from the s.c. injection. Thus, we compared three different routes of immunization (s.c., i.p., and f.p.) using FUW-hgp100/ SVGmu. Although anti-gp100 T-cell responses were observed for all three routes, the f.p. immunization generated the highest immune response, as confirmed by both tetramer staining and intracellular cytokine staining. These results indicate that the choice of immunization route for this type of targeting vectors does impact the resulting level of vaccine-induced immune responses. One possible explanation for the superiority of the f.p. injection is that there is both a local enrichment of DCs and slow diffusion of the vector at the f.p. area, which may result in higher numbers of DCs targeted. We are designing experiments such as those described by Falo and coworkers, 56 to track the transduced DCs and their migration to secondary lymphoid tissues to further understand the mechanism of immune induction by different routes of vaccine administration.
We found that a single dose f.p. injection of the engineered lentivector to naı¨ve mice was sufficient to elicit both cellular and humoral immune responses against the hgp100 antigen. We are encouraged to see such a high level response from a rather modest dose of the vaccine vector (5 Â 10 6 TU/mouse). Next, we tracked the frequency of hgp100-specific T cells in the peripheral blood after a singledose prime vaccination and observed a rapid expansion phase of antigen-specific T cells between week one and week three postimmunization. The antigen-specific CD8 þ T-cell population peaked (up to 10%) at week three. Although the number of antigen-specific CD8 þ T cells declined thereafter, a relatively high level (around 5%) of cells were maintained for up to 8 weeks. The exact reason for such a prolonged contraction kinetics remains unclear, but we speculate that it could be contributed by the targeting feature of the vector capable of selectively delivering antigenic genes to DCs. These DCs then are able to stably present antigens to efficiently stimulate high quality antigenspecific immune responses.
Although it was proposed that the HIV-1-based lentivector should have limited anti-vector immunity due to the minimal viral gene expression, it remained to be evaluated for the level of the vector-specific immune responses upon immunization with the DC-directed lentivector. Thus, we assessed the degree of functionally significant anti-vector immune responses in mice. A single f.p. injection of FUGW/SVGmu resulted in a relatively lower level of neutralizing antibodies against the vector. At the dose of 10 3 ng p24, the non-targeting vector (FUGW/VsVg) generated more than 10-fold higher neutralizing antibodies than that from the DC-directed FUGW/SVGmu. This evidence of low anti-vector immunity suggests that a homologous prime/boost strategy using the DC-directed lentivector could further augment the hgp100-specific immune responses. Although the experiment is underway to test this hypothesis, we indeed observed a markedly enhanced immunity by multiple rounds of immunization in a HIV-1 Gag antigen model. 52 An in vivo challenge experiment using the B16 murine melanoma model showed a significant inhibition of tumor growth in mice vaccinated with one round of the FUWhgp100/SVGmu vector. Compared with the control groups, the targeting vector encoding hgp100 was clearly able to induce tumor-specific immunity to slow the growth of the aggressive B16 melanoma cells. The in vivo depletion of CD8 þ T cells further suggests that these T cells contribute to the anti-tumor immunity generated by the vectored immunization. However, the single-dose vaccine was unable to completely protect mice from the tumor challenge. There could be many complicated reasons for this observation, among them a possible immune tolerance to the gp100 antigen. Many studies have demonstrated that anti-tumor immunity and the ability to break tolerance could be enhanced by co-delivering additional immunomodulator genes, such as interleukin-2, interleukin-12, interleukin-15, CD70 and other activators, to DCs. 5, [57] [58] [59] [60] We are currently conducting experiments to evaluate the anti-tumor immunity generated by the co-delivery of a tumor antigen and an immuomodulator using this DC-directed lentivector system.
In conclusion, we demonstrated that a targeting lentivector vaccine carrying the hgp100 antigen could elicit efficient antigen-specific humoral and cellular immune responses in a mouse model. A single-dose f.p. injection of the vector induced sufficient tumor-protective immunity to inhibit the growth of B16 murine melanoma. This vectored vaccine strategy can be readily adapted to other disease models by simply replacing the encoded immunogen. Further studies will also focus on the manipulation of the tolerance-mediating pathways in DCs via co-delivery of various immunomodulators. A therapeutic immunization model, in which animals are transplanted with tumors before vectored vaccines, can be further used to gauge the full potential of this novel vaccine modality against cancer.
